Novavax to Participate in Upcoming Conferences

Rhea-AI Summary

On January 6, 2021, Novavax (Nasdaq: NVAX) announced participation in two investor conferences, focusing on its COVID-19 vaccine candidate, NVX-CoV2373. The J.P. Morgan Healthcare Conference will take place on January 11, 2021, featuring presentations by key executives, including CEO Stanley C. Erck. Additionally, the 13th Annual Biotech Showcase is scheduled for January 8, 2021, with a panel discussing Novavax's journey during the pandemic. NVX-CoV2373, a protein-based vaccine, has shown promising results in clinical trials and is currently in pivotal Phase 3 evaluations.

GAITHERSBURG, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion in each presentation.

J.P. Morgan 39th Annual Healthcare Conference
Presentation
Date:	Monday, January 11, 2021
Time:	8:20 a.m. Eastern Time (ET)
Presenters:	Stanley C. Erck, President and Chief Executive Officer and Gregory M. Glenn, M.D., President, Research and Development
Webcast:	www.novavax.com, “Investors” / “Events”
Conference
Event:	Investor meetings
Date:	Monday, January 11, 2021 – Wednesday, January 13, 2021

13th Annual Biotech Showcase
Panel
Date:	Friday, January 8, 2021
Time:	11:00 a.m. Eastern Time (ET)
Panel title:	In Conversation with COVID-19 Leaders: The Novavax COVID-19 Journey
Moderator:	Kimberly Ha, Founder and Chief Executive Officer, KKH Advisors
Panelist:	John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, Novavax
Webcast:	A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.

About NVX-CoV2373
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein. It is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease. NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in Phase 1/2 clinical testing. NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the U.K that completed enrollment in November and a trial in the U.S. and Mexico that began in December. It is also being tested in two ongoing Phase 2 studies that began in August: a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia.

About Matrix-M™
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The Company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Novavax Forward Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, and Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:         
Investors
Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
media@novavax.com
617-974-8659

FAQ

What is Novavax's COVID-19 vaccine candidate NVX-CoV2373?

NVX-CoV2373 is a protein-based vaccine candidate created from the genetic sequence of SARS-CoV-2, designed to induce a robust immune response.

When is Novavax presenting at the J.P. Morgan Healthcare Conference?

Novavax will present at the J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 a.m. ET.

What topics will be discussed at the 13th Annual Biotech Showcase?

The panel at the 13th Annual Biotech Showcase on January 8, 2021, will focus on Novavax's COVID-19 journey.

What is the status of NVX-CoV2373 clinical trials?

NVX-CoV2373 is currently undergoing two pivotal Phase 3 trials in the U.K. and the U.S., with additional Phase 2 studies in progress.

Who are the key presenters for Novavax at the upcoming conferences?

Stanley C. Erck, President and CEO, and Gregory M. Glenn, M.D., President of Research and Development, will present at the conferences.